JP2022535072A5 - - Google Patents

Info

Publication number
JP2022535072A5
JP2022535072A5 JP2021571744A JP2021571744A JP2022535072A5 JP 2022535072 A5 JP2022535072 A5 JP 2022535072A5 JP 2021571744 A JP2021571744 A JP 2021571744A JP 2021571744 A JP2021571744 A JP 2021571744A JP 2022535072 A5 JP2022535072 A5 JP 2022535072A5
Authority
JP
Japan
Prior art keywords
compound
peaks
xrpd pattern
theta scale
following
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021571744A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022535072A (ja
JP7579281B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/065980 external-priority patent/WO2020247019A1/en
Publication of JP2022535072A publication Critical patent/JP2022535072A/ja
Publication of JP2022535072A5 publication Critical patent/JP2022535072A5/ja
Application granted granted Critical
Publication of JP7579281B2 publication Critical patent/JP7579281B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021571744A 2019-06-03 2019-12-12 キナーゼ阻害剤の結晶性塩形態 Active JP7579281B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962856404P 2019-06-03 2019-06-03
US62/856,404 2019-06-03
PCT/US2019/065980 WO2020247019A1 (en) 2019-06-03 2019-12-12 Crystalline salt forms of a kinase inhibitor

Publications (3)

Publication Number Publication Date
JP2022535072A JP2022535072A (ja) 2022-08-04
JP2022535072A5 true JP2022535072A5 (cg-RX-API-DMAC7.html) 2022-12-19
JP7579281B2 JP7579281B2 (ja) 2024-11-07

Family

ID=69160360

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021571744A Active JP7579281B2 (ja) 2019-06-03 2019-12-12 キナーゼ阻害剤の結晶性塩形態

Country Status (22)

Country Link
US (1) US20230052703A1 (cg-RX-API-DMAC7.html)
EP (1) EP3976587B1 (cg-RX-API-DMAC7.html)
JP (1) JP7579281B2 (cg-RX-API-DMAC7.html)
KR (1) KR102826380B1 (cg-RX-API-DMAC7.html)
CN (1) CN113939503B (cg-RX-API-DMAC7.html)
AU (1) AU2019449809B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021024300A2 (cg-RX-API-DMAC7.html)
CA (1) CA3139148A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021003205A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021017343A2 (cg-RX-API-DMAC7.html)
CR (1) CR20210616A (cg-RX-API-DMAC7.html)
DO (1) DOP2021000236A (cg-RX-API-DMAC7.html)
ES (1) ES3008963T3 (cg-RX-API-DMAC7.html)
GE (2) GEP20247655B (cg-RX-API-DMAC7.html)
IL (1) IL288484A (cg-RX-API-DMAC7.html)
MA (1) MA56001A (cg-RX-API-DMAC7.html)
MX (1) MX2021014773A (cg-RX-API-DMAC7.html)
PE (1) PE20220962A1 (cg-RX-API-DMAC7.html)
PH (1) PH12021553020A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202111978VA (cg-RX-API-DMAC7.html)
WO (1) WO2020247019A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202108034B (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20251184T1 (hr) * 2018-01-26 2025-12-05 Exelixis, Inc. Spojevi za liječenje poremećaja ovisnih o kinazi
PL3894012T4 (pl) * 2018-12-13 2026-01-05 Exelixis, Inc. Postacie krystaliczne i postacie soli inhibitora kinazy
AR127561A1 (es) * 2021-11-03 2024-02-07 Exelixis Inc Compuestos para el tratamiento de trastornos dependientes de cinasas
AU2022420610A1 (en) 2021-12-22 2024-06-27 Exelixis, Inc. Crystalline forms and salt forms of a kinase inhibitor
CN116751161A (zh) * 2023-06-28 2023-09-15 中国人民解放军军事科学院军事医学研究院 喹啉类化合物及其制备方法、药物组合物及医药用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2210607B1 (en) 2003-09-26 2011-08-17 Exelixis Inc. N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer
WO2006113546A2 (en) 2005-04-15 2006-10-26 Neogenix Oncology, Inc. Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
SG187064A1 (en) * 2010-07-14 2013-02-28 Zhejiang Beta Pharma Inc NOVEL FUSED HETEROCYCLIC DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS
BR112015007672A2 (pt) 2012-10-04 2017-08-08 Dana Farber Cancer Inst Inc anticorpos anti-pd-l1 monoclonais humanos e métodos de uso
RS61400B1 (sr) 2013-05-02 2021-02-26 Anaptysbio Inc Antitela usmerena protiv programirane smrti-1 (pd-1)
US20180009758A1 (en) * 2015-06-29 2018-01-11 Ontogenesis, Llc Multi-Tyrosine Kinase Inhibitors Derivatives and Methods of Use
MX2019012505A (es) * 2017-05-26 2019-12-19 Exelixis Inc Formas solidas cristalinas de sales de ciclopropano-1,1-dicarboxam ida de n-{4-[(6,7-dimetoxiquinolin-4-il)oxi]fenil}-n'-(4-fluorofen il), procesos para realizarlas y metodos de uso.
HRP20251184T1 (hr) * 2018-01-26 2025-12-05 Exelixis, Inc. Spojevi za liječenje poremećaja ovisnih o kinazi
PL3894012T4 (pl) * 2018-12-13 2026-01-05 Exelixis, Inc. Postacie krystaliczne i postacie soli inhibitora kinazy
CN109761899B (zh) * 2019-02-14 2022-11-15 广州六顺生物科技股份有限公司 喹啉衍生物、其药学上可接受的盐或其溶剂合物、其应用、药物及药物组合物

Similar Documents

Publication Publication Date Title
CN106795144B (zh) 用于调节egfr突变体激酶活性的化合物和组合物
DK2383268T3 (en) PYRAZOLYLAMINOPYRIDINDERIVATER useful as kinase inhibitors
JP2011515370A (ja) 4−アミノ−5−フルオロ−3−[5−(4−メチルピペラジン−1−イル)−1h−ベンズイミダゾール−2−イル]キノリン−2(1h)−オン乳酸塩の結晶形態及び2つの溶媒和物形態
JP2015510890A5 (cg-RX-API-DMAC7.html)
JP6896701B2 (ja) イミダゾリルアミド誘導体
KR102142797B1 (ko) 피리디닐아미노피리미딘 유도체의 메실레이트 염의 결정질 형태, 그의 제조 방법, 및 그의 용도
TW200932727A (en) New acetyl coenzyme a carboxylase (ACC) inhibitors and uses in treatments of obesity and diabetes mellitus
JP2020511515A5 (cg-RX-API-DMAC7.html)
JP2010505961A5 (cg-RX-API-DMAC7.html)
KR20180117697A (ko) 피리디닐아미노피리미딘 유도체의 염, 그의 제조 방법, 및 그의 용도
KR20100131007A (ko) 레닌 억제제로서의 3,4-치환된 피페리딘 유도체
AU2022205604A1 (en) Selective inhibitors of rock1 and rock2 protein kinases and uses thereof
KR20200011388A (ko) Jnk 저해 활성을 갖는 신규한 이미다졸 유도체 및 이를 포함하는 약학적 조성물
TW201840533A (zh) 熱休克蛋白90抑制劑
JPWO2009041559A1 (ja) インダゾールアクリル酸アミド化合物
US10138221B2 (en) Salts of nilotinib and polymorphs thereof
KR20180011772A (ko) 신규 아미도헤테로아릴 아로일 히드라지드 에틴
JP2019529553A (ja) 結晶形
JP2021523120A5 (cg-RX-API-DMAC7.html)
JP2023539635A (ja) ヒストンリジンデメチラーゼ阻害のための化合物、組成物および方法
KR102205619B1 (ko) 신규한 인다졸 유도체 화합물 및 이를 포함하는 암의 예방, 개선 또는 치료용 약학 조성물
CN106573928A (zh) 2‑氨基噻唑衍生物或其盐
CN103570673B (zh) 一种甲磺酸伊马替尼α晶型的制备方法
TH2101007514A (th) รูปแบบของเกลือที่เป็นผลึกของสารยับยั้งไคเนส
WO2010083720A1 (zh) 光学纯喹唑啉类化合物